PIK3CA and ovarian carcinoma: Recently, Passarelli et al. reported the outcomes of patients with PIK3CA-mutated recurrent gynecological tumors, including 10 ovarian cancers, prospectively treated with alpelisib within a controlled program (NCT04085653) [53].